Eyepoint Pharmaceuticals Share Price (NASDAQ: EYPT)

$11.44

▲

-0.16

(-1.38%)

Live

Last updated on August 30, 2025 at 12:40 am IST

$₹

Check the interactive Eyepoint Pharmaceuticals Stock chart to analyse performance

Eyepoint Pharmaceuticals stock performance

as on August 30, 2025 at 12:40 am IST

Today's Low:$11.26
Today's High:$11.65
$11.44
1.57%
Downside
Day's Volatility :3.31%
Upside
1.76%
52 Weeks Low:$3.91
52 Weeks High:$13.99
$11.44
65.82%
Downside
52 Weeks Volatility :72.04%
Upside
18.2%

Eyepoint Pharmaceuticals Stock Returns

Period	Eyepoint Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	60.36%	3.1%	0.0%
6 Months	85.17%	-8.4%	0.0%
1 Year	33.14%	-12.6%	0.0%
3 Years	16.92%	7.9%	-6.1%

Eyepoint Pharmaceuticals Inc Key Stats

Check Eyepoint Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$11.6
Open	$11.84
Today's High	$11.645
Today's Low	$11.26
Market Capitalization	$816.1M
Today's Volume	$496.3K
52 Week High	$13.985
52 Week Low	$3.91
Revenue TTM	$51.9M
EBITDA	$-187.1M
Earnings Per Share (EPS)	$-2.69
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-73.95%

Stock Returns calculator for Eyepoint Pharmaceuticals Stock including INR - Dollar returns

The Eyepoint Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Eyepoint Pharmaceuticals investment value today

Current value as on today

₹1,36,370

Returns

₹36,370

(+36.37%)

Returns from Eyepoint Pharmaceuticals Stock

₹31,193 (+31.19%)

Dollar Returns*

₹5,177 (+5.18%)

Indian investors sentiment towards Eyepoint Pharmaceuticals Stock

-83%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Eyepoint Pharmaceuticals Stock from India on INDmoney has decreased by -83% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Eyepoint Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
Cormorant Asset Management, LLC
12.08%
Suvretta Capital Management, LLC
9.87%
Adage Capital Partners Gp LLC
8.99%
BlackRock Inc
8.30%
Federated Hermes Inc
6.67%
Franklin Resources Inc
6.24%

Analyst Recommendation on Eyepoint Pharmaceuticals Stock

Rating

Trend

Buy

93%Buy

6%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Eyepoint Pharmaceuticals(by analysts ranked 0 to 5 stars)

Eyepoint Pharmaceuticals Share Price Target

What analysts predicted

Upside of 200.85%

Target:

$34.42

Current:

$11.44

Eyepoint Pharmaceuticals share price target is $34.42, a slight Upside of 200.85% compared to current price of $11.44 as per analysts' prediction.

Eyepoint Pharmaceuticals Stock Insights

Price Movement
In the last 3 months, EYPT stock has moved up by 61.0%
Decreasing Revenue
Revenue is down for the last 2 quarters, 24.45M → 5.33M (in $), with an average decrease of 78.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -29.36M → -59.42M (in $), with an average decrease of 27.2% per quarter
EYPT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.5% return, outperforming this stock by 24.4%
EYPT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.3% return, outperforming this stock by 103.0%
Price to Sales
ForEYPT every $1 of sales, investors are willing to pay $14.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.8 for every $1 of sales.

Eyepoint Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$20.4M	↑ 587.77%
Net Income	$-63.0M	↑ 18.43%
Net Profit Margin	-309.2%	↑ 1486.51%

	FY20	Y/Y Change
Revenue	$34.4M	↑ 69.1%
Net Income	$-52.7M	↓ 16.39%
Net Profit Margin	-152.89%	↑ 156.31%

	FY21	Y/Y Change
Revenue	$36.9M	↑ 7.27%
Net Income	$-63.9M	↑ 21.39%
Net Profit Margin	-173.03%	↓ 20.14%

	FY22	Y/Y Change
Revenue	$41.4M	↑ 12.09%
Net Income	$-124.5M	↑ 94.81%
Net Profit Margin	-300.72%	↓ 127.69%

	FY23	Y/Y Change
Revenue	$46.0M	↑ 11.14%
Net Income	$-70.8M	↓ 43.14%
Net Profit Margin	-153.84%	↑ 146.88%

	FY24	Y/Y Change
Revenue	$43.3M	↓ 5.97%
Net Income	$-130.9M	↑ 84.86%
Net Profit Margin	-302.43%	↓ 148.59%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$11.7M	↓ 16.71%
Net Income	$-29.3M	↑ 107.7%
Net Profit Margin	-250.63%	↓ 150.12%

	Q2 FY24	Q/Q Change
Revenue	$9.5M	↓ 18.89%
Net Income	$-30.8M	↑ 5.27%
Net Profit Margin	-325.27%	↓ 74.64%

	Q3 FY24	Q/Q Change
Revenue	$10.5M	↑ 11.05%
Net Income	$-29.4M	↓ 4.75%
Net Profit Margin	-278.99%	↑ 46.28%

	Q4 FY24	Q/Q Change
Revenue	$11.6M	↑ 10.11%
Net Income	$-41.4M	↑ 41.0%
Net Profit Margin	-357.26%	↓ 78.27%

	Q1 FY25	Q/Q Change
Revenue	$24.5M	↑ 111.02%
Net Income	$-45.2M	↑ 9.17%
Net Profit Margin	-184.82%	↑ 172.44%

	Q2 FY25	Q/Q Change
Revenue	$5.3M	↓ 78.19%
Net Income	$-59.4M	↑ 31.49%
Net Profit Margin	-1.1K%	↓ 929.49%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$17.7M	↓ 213.75%

	FY20	Y/Y Change
Profit	$28.6M	↑ 61.86%

	FY21	Y/Y Change
Profit	$28.8M	↑ 0.52%

	FY22	Y/Y Change
Profit	$33.1M	↑ 15.01%

	FY23	Y/Y Change
Profit	$41.4M	↑ 25.12%

	FY24	Y/Y Change
Profit	$39.6M	↓ 4.41%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$10.9M	↓ 16.16%

	Q2 FY24	Q/Q Change
Profit	$8.1M	↓ 26.08%

	Q3 FY24	Q/Q Change
Profit	$9.8M	↑ 21.2%

	Q4 FY24	Q/Q Change
Profit	$10.8M	↑ 10.05%

	Q1 FY25	Q/Q Change
Profit	$23.6M	↑ 119.53%

	Q2 FY25	Q/Q Change
Profit	$5.2M	↓ 78.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-56.7M	↑ 158.82%
Investing Cash Flow	$-213.0K	↓ 98.74%
Financing Cash Flow	$33.9M	↓ 44.18%

	FY20	Y/Y Change
Operating Cash Flow	$-14.4M	↓ 74.54%
Investing Cash Flow	$-362.0K	↑ 69.95%
Financing Cash Flow	$37.5M	↑ 10.71%

	FY21	Y/Y Change
Operating Cash Flow	$-50.1M	↑ 247.05%
Investing Cash Flow	$-33.1M	↑ 9049.45%
Financing Cash Flow	$216.9M	↑ 478.53%

	FY22	Y/Y Change
Operating Cash Flow	$-65.0M	↑ 29.76%
Investing Cash Flow	$-17.3M	↓ 47.87%
Financing Cash Flow	$-690.0K	↓ 100.32%

	FY23	Y/Y Change
Operating Cash Flow	$1.9M	↓ 102.88%
Investing Cash Flow	$-3.3M	↓ 80.8%
Financing Cash Flow	$187.1M	↓ 27211.59%

	FY24	Y/Y Change
Operating Cash Flow	$-126.2M	↓ 6832.05%
Investing Cash Flow	$-219.4M	↑ 6517.04%
Financing Cash Flow	$164.0M	↓ 12.32%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-31.2M	↑ 34.89%
Investing Cash Flow	$20.8M	↓ 144.13%
Financing Cash Flow	$115.0K	↓ 99.95%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-20.2M	↓ 35.27%
Investing Cash Flow	$-160.4M	↓ 870.91%
Financing Cash Flow	$329.0K	↑ 186.09%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-39.0M	↑ 93.42%
Investing Cash Flow	$16.2M	↓ 110.1%
Financing Cash Flow	$11.9M	↑ 3514.89%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-35.8M	↓ 8.15%
Investing Cash Flow	$-96.0M	↓ 692.5%
Financing Cash Flow	$151.7M	↑ 1175.41%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-53.1M	↑ 48.18%
Investing Cash Flow	$39.5M	↓ 141.19%
Financing Cash Flow	$-951.0K	↓ 100.63%

Eyepoint Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Eyepoint Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Eyepoint Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Eyepoint Pharmaceuticals Inc	17.99%	85.17%	33.14%	16.92%	116.97%
Regeneron Pharmaceuticals, Inc.	3.77%	-17.64%	-51.18%	-2.19%	-7.17%
Beone Medicines Ltd	-0.02%	10.33%	51.07%	81.16%	24.14%
Vertex Pharmaceuticals Incorporated	-16.39%	-18.24%	-20.49%	39.42%	40.54%
Alnylam Pharmaceuticals, Inc.	33.05%	83.22%	57.52%	115.32%	240.85%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Eyepoint Pharmaceuticals Inc	NA	NA	NA	-3.03	-0.74	-0.38	NA	3.57
Regeneron Pharmaceuticals, Inc.	14.79	14.79	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.69	27.69	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Eyepoint Pharmaceuticals Inc	Buy	$816.1M	116.97%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$62.2B	-7.17%	14.79	31.37%
Beone Medicines Ltd	NA	$36.8B	24.14%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.8B	40.54%	27.69	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	240.85%	NA	-12.96%

About Eyepoint Pharmaceuticals Inc

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Organization	Eyepoint Pharmaceuticals
Employees	165
CEO	Dr. Anna Kluczewska
Industry	Health Technology

Key Management of Eyepoint Pharmaceuticals Inc

Name	Title
Dr. Jay S. Duker M.D.	President, CEO & Director
Mr. George O. Elston CPA	Executive VP & CFO
Dr. Ramiro Ribeiro M.D., Ph.D.	Chief Medical Officer
Dr. Marcia Sellos-Moura Ph.D.	Chief Scientific Officer
Mr. Ron I. Honig Esq.	Chief Legal Officer & Company Secretary
Ms. Jennifer Leonard	Chief People Officer & Senior VP of IT
Mr. David Scott Jones M.A.	Senior VP & Chief Commercial Officer
Ms. Isabelle Lefebvre	Chief Regulatory Officer
Mr. Michael J. Maciocio	Chief Manufacturing Officer
Dr. Anna Kluczewska	CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Important FAQs about investing in EYPT Stock from India :

What is Eyepoint Pharmaceuticals share price today?

Eyepoint Pharmaceuticals share price today is $11.44 as on August 30, 2025 at 12:40 am IST. Eyepoint Pharmaceuticals share today touched a day high of $11.65 and a low of $11.26.

What is the 52 week high and 52 week low for Eyepoint Pharmaceuticals share?

Eyepoint Pharmaceuticals share touched a 52 week high of $13.99 and a 52 week low of $3.91. Eyepoint Pharmaceuticals stock price today i.e. August 30, 2025 at 12:40 am IST is trending at $11.44, lower by 18.2% versus the 52 week high.

How to invest in Eyepoint Pharmaceuticals Stock (EYPT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Eyepoint Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eyepoint Pharmaceuticals Shares that will get you 0.1311 shares as per Eyepoint Pharmaceuticals share price of $11.44 per share as on August 30, 2025 at 12:40 am IST.

What is the minimum amount required to buy Eyepoint Pharmaceuticals Stock (EYPT) from India?

Indian investors can start investing in Eyepoint Pharmaceuticals (EYPT) shares with as little as ₹88.167 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.67 in Eyepoint Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Eyepoint Pharmaceuticals share’s latest price of $11.44 as on August 30, 2025 at 12:40 am IST, you will get 0.8741 shares of Eyepoint Pharmaceuticals. Learn more about fractional shares .

What are the returns that Eyepoint Pharmaceuticals has given to Indian investors in the last 5 years?

Eyepoint Pharmaceuticals stock has given 116.97% share price returns and 20.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?